KLRK1 and neoplasm: On the other hand, tumor-directed recombinant ligands that engage NKG2D may also enhance tumor cell targeting, as recently documented against malignant B cells for bispecifics composed of CD20-binding and NKG2D ligand (MICA or ULBP2) domains (52).